We are proud to now be offering Vabysmo a novel new treatment for Wet Age Related Macular Degeneration.
The FDA approval of Vabysmo comes after four studies were conducted supporting its effectiveness In these trials, which included over 4,000 total participants, Vabysmo was compared with Regenron’s Eylea, currently the most commonly used treatment for both wet AMD and DME.
Vabysmo works by targeting and inhibiting two disease pathways that are thought to destabilize blood vessels in the eye, causing new leaky blood vessels to form and increasing inflammation. By stopping these blood vessels from growing, Vabysmo may decrease the risk of bleeding and fluid buildup in the eyes.
Vabysmo is the first bispecific antibody designed for the eye, which means that it simultaneously treats two targets causing eye disease instead of the single target we have treated for the past 15 years.”
In all four studies, researchers concluded that Vabysmo was as effective as Eylea in treating vision loss from wet AMD and DME. In addition, Vabysmo also caused fewer side effects and was associated with fewer health risks than Eylea.
Perhaps the most significant advantage of Vabysmo is the potentially reduced frequency of treatment. Both Vabysmo and Eylea are administered by injection to the eye, requiring a clinic visit. In the most recent studies, over half the participants on Vabysmo went four months between treatments while maintaining improvements in vision after the initial administration of monthly eye injections; over 75% maintained vision improvements with at least three months between treatments.
In comparison, people on Eylea receive injections bimonthly. These study results demonstrate that not only does this new treatment potentially reduce the frequency of required in-clinic visits and injections to the eye, but it could also reduce the cost of treatment based on the need for fewer doses. The decreased injection frequency may also improve quality of life.
Please contact our office a 703-528-3910 to schedule a consultation to evaluate your eyes for potential macular degeneration and to discuss treatment options.